Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To evaluate the safety, tolerability and efficacy (SVR-12) of 12 or 24 weeks of treatment with an IFN-free regimen of STV, DNV/r, and RBV, with or without MCB, in treatment-naïve CHC genotype 1 patients.
Critère d'inclusion
- Chronic Hepatitis C genotype 1